Proceedings of the 13th International Congress of the World Equine Veterinary Association WEVA

Similar documents
The Equine Stomach. by: Multiple Authors March , Article # 5068

Equine Gastric Ulcer Syndrome

GASTRIC ULCERATION. Gastroduodenoscopy This is the term for scoping the stomach and the duodenum.

Equine gastric squamous and glandular disease update

Ulcers in the Stomach and Colon; Diagnosis and Treatment: A Pain in the Gut!

The Effect of EGUSIN SLH and EGUSIN 250 on Reducing Gastric Ulcer Scores in Thoroughbred Horses Final Report April 12, 2011

NSAIDs: the Past, Present, and Future

Esophago-gastroduodenal ulceration complicated by duodenal perforation in a three year old Thoroughbred colt: a case report

- Federal (USA) law restricts this drug to use by or on the order of a licensed veterinarian.

Effects of Intravenously Administrated Omeprazole on Gastric Juice ph and Gastric Ulcer Scores in Adult Horses

Randlab Gastroscopy Standard Operating Procedure RANDLAB. Veterinary Medicines.

UNDERSTANDING COLIC: DON T GET IT TWISTED

The term Equine Gastric Ulcer Syndrome (EGUS)

Non-steroidal anti-inflammatory drugs (NSAIDs) are used widely to relieve pain, with or without

Pyloric ulceration and stenosis in a two-year-old thoroughbred filly: a case report

A comparison of three doses of omeprazole in the treatment of equine gastric ulcer syndrome: A blinded, randomised, dose response clinical trial

Treatment of Helicobacter pylori infection in adults

Gastric Dilatation-Volvulus

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS. Medicinal product no longer authorised

SUMMARY OF PRODUCT CHARACTERISTICS. 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Emdocam 20 mg/ml solution for injection for cattle, pigs and horses

The Royal College of Veterinary Surgeons DIPLOMA IN EQUINE SOFT TISSUE SURGERY PAPER I. (Basic Sciences) Tuesday 2 May 1995

December 2010, Issue 26. Season's Greetings from all of us at AMVS to all of you! May your holidays be bright and your new year abundant.

Summary of Product Characteristics

Metacam is an anti-inflammatory medicine used in cattle, pigs, horses, dogs, cats and guinea pigs.

Australian and New Zealand College of Veterinary Scientists. Membership Examination. Medicine of Horses Paper 1

The Prevalence of NSAID related ulcer and Helicobacter pylori related ulcer in Hasan Sadikin General Hospital Bandung Indonesia.

Summary of Product Characteristics

Canine and Feline Foreign Bodies To Cut or Not to Cut? Dr. Jinelle Webb, MSc, DVSc, Diplomate ACVIM

The Institutional Animal Care and Use Committee (IACUC) Aquatic Animals: Analgesia and Anesthesia formulary

Acute Hemorrhagic Diarrhea Syndrome (AHDS) A Cause of Bloody Feces in Dogs

Infection Comments First Line Agents Penicillin Allergy History of multiresistant. line treatment: persist for >7 days they may be

Management of Equine Colic in Veterinary Practice Derek Major Agnes Banks Equine Clinic

SUMMARY OF PRODUCT CHARACTERISTICS

ARCI Controlled Therapeutic Medication Schedule for Horses - Version 3.2 Revised December 9, 2016.

Treatment of septic peritonitis

ARCI Controlled Therapeutic Medication Schedule for Horses - Version 4.1 Revised January, 2019

SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT

New Maryland Racing Medication Guidelines

Oral and intestinal candidiasis. As adjuvant treatment with other local nystatin preparations to prevent reinfection.

POST-OPERATIVE ANALGESIA AND FORMULARIES

Myth #1 - "Feeding my dog raw meat will make him aggressive!"

peer reviewed Right dorsal colitis in the horse: minireview and reports on three cases in Ireland

Acute Laminitis in the UK The Redwings Study

Feline Lower Urinary Tract Disease FLUTD

Gastric ulcers are highly prevalent in performance

Metacam 1.5 mg/ml oral suspension for dogs

WITHDRAWAL TIME RECOMMENDATIONS ARIZONA RACE TRACKS MEET

Caution: Federal law restricts this drug to use by or on the order of a licensed veterinarian.

ARCI Controlled Therapeutic Medication Schedule for Horses - Version 2.2 Revised April 2015

DAM (1929) as reported by Cheney

NSAIDs Are You Following the Rules?

E-BOOK - WHAT TO DO FOR AN ULCER DOWNLOAD

S100A12 concentrations and myeloperoxidase activities are increased in the intestinal mucosa of dogs with chronic enteropathies

Prescription Label. Patient Name: Species: Drug Name & Strength: Directions (amount to give how often & for how long):

Final Report. Project code: P.PSH.0653 Prepared by: Fiona Cotter Troy Laboratories Pty Ltd Date published: July 2014

Maryland Racing Commission Medication Guidelines

Summary of Product Characteristics

Understanding your pet s LIVER CONDITION

Feline lower urinary tract disease (FLUTD)

Just where it s needed.

CHECKLIST. Owner. Veterinarian. Horse. Laminitis - understanding, cure, prevention. Name: Address: City: Phone: Postal code: Mobile phone:

Pain management in equine patients therapy options

Equine Emergencies. Identification and What to do Until the Vet Arrives Kathryn Krista, DVM, MS

CHAPTER 45. PROHIBITED PRACTICES AND EQUINE TESTING

Payback News. Beef Herd Nutrition Challenges

Inflammatory pain in cattle

NSAID Toxicity in Dogs & Cats Beware of Ibuprofen!

Therapeutic apheresis in veterinary

Pain Management in Racing Greyhounds

SUMMARY OF PRODUCT CHARACTERISTICS

Index. Note: Page numbers of article titles are in boldface type.

SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT

SUMMARY OF PRODUCT CHARACTERISTICS. Animeloxan 1.5 mg/ml oral suspension for dogs. Active substance: Meloxicam 1.5 mg (equivalent to 0.

Intestinal linear foreign body

SUMMARY OF PRODUCT CHARACTERISTICS

Introducing the latest in worming technology...

EPAR type II variation for Metacam

We are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists. International authors and editors

Equine Diseases. Dr. Kashif Ishaq. Disease Management

Metacam. The Only NSAID Approved for Cats in the US. John G. Pantalo, VMD Professional Services Veterinarian. Think easy. Think cat. Think METACAM.

Commonly Used Analgesics

Irish Medicines Board

Burn Infection & Laboratory Diagnosis

Australian College of Veterinary Scientists. Fellowship Examination. Small Animal Surgery Paper 1

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

Oral and intestinal candidiasis. As adjuvant treatment with other local nystatin preparations to prevent reinfection.

American Association of Feline Practitioners American Animal Hospital Association

CLPNA Pressure Ulcers ecourse: Module 5.6 Quiz II page 1

SUMMARY OF PRODUCT CHARACTERISTICS

Meloxicam withdrawal time veterinarian bovine

Understanding your cat s FOOD ALLERGIES

H. PYLORI CLOSED REFERRAL STATUS: Dear Dr.,

PHAMACOLOGY 2 nd EXAM QUESTIONS 2012/2013

Proceedings of the 13th International Congress of the World Equine Veterinary Association WEVA

Don t let arthritis slow down your dog!

Case-Control Study of Pasture- and Endocrinopathy- Associated Laminitis in Horses

Meloxicam vs etodolac cox 2 inhibition

They are updated regularly as new NICE guidance is published. To view the latest version of this NICE Pathway see:

Copper-Storage Liver Disease Basics

Transcription:

www.ivis.org Proceedings of the 13th International Congress of the World Equine Veterinary Association WEVA October 3-5, 2013 Budapest, Hungary Reprinted in IVIS with the Permission of the WEVA Organizers

Equine Gastric Ulcer Syndrome (EGUS) Barbora Bezdekova University of Veterinary and Pharmaceutical Sciences, Faculty of Veterinary Medicine, Equine Clinic, Brno, Czech Republic Introduction Equine gastric ulcer syndrome (EGUS) is characterized by ulceration of the distal esophagus, stomach (proximal squamous or nonglandular mucosal part, distal glandular part) and proximal duodenum. EGUS represents a significant clinical and economic problem in horses due to its high prevalence, nonspecific clinical picture and negative effect on the horse s performance. All ages and both sexes of horses are susceptible to EGUS. Even the exact ethiology is not clear yet, factors including exercise, stress, feed management, administration of nonsteroidal drugs, microbial infection and several others have been discussed. Identifying the real cause of gastric and duodenal ulceration in horses can lead to specific therapy and thus disease eradication. Recent antiulcer treatment options are expensive and their effect is usually only short-term. Therefore the recurrence of EGUS is common and it increases the clinical importance of this disease. Mechanism of the disease An increase in aggressive factors including acid content, decreased ph and decrease in protective mucosal factors have been confirmed as causes for gastric ulceration in horses. Horses are continuous gastric acid secretors. The hydrochloric acid and gastric ph lower than 4.0 are the most important pathogenetic causes of gastric ulceration in horses. The proximal third of the equine stomach is lined with nonglandular stratified squamous epithelium. Nonglandular stomach mucosa is predisposed to acid injury because it does not secrete any protective substance such as mucus or bicarbonate. Gastric ph is higher in the nonglandular part of the equine stomach in comparison with the glandular part. HCl induces injury in this mucosal type by damaging the outer cell barrier, followed later by diffusion into the squamous cells of the stratum spinosum resulting in inhibition of cellular sodium transport, cell swelling and ulceration. The distal two thirds of the equine stomach are lined with glandular mucosa. This mucosal part is responsible for hydrochloric acid (HCl) and pepsinogen secretion as well as for protective mucus and bicarbonate layer production. The dense capillary network in the glandular mucosa is an important factor in mucosal secretion and its healing properties, but gastric ulcerations affect both mucosal parts in horses.

Prevalence Equine gastric ulcer syndrome seems to be extremely prevalent in the equine population. EGUS was first described as a serious highly prevalent disease of foals in 1964. Later, frequent occurrence of the syndrome in adult horses was also found. According to various authors, prevalence of the disease varies from 55% to 100%. Erosion and ulceration of the gastric mucosa is a common finding in racehorses. Racing Thorougbreds were found to have a prevalence as high as 97%. Equine gastric ulceration syndrome is highly prevalent in Standardbred racehorses too (63% in the Czech Rebublic). Similarly high EGUS prevalence was found within endurance horses. Horses used for pleasure, riding lessons or show have a lower EGUS prevalence (37%) and severity of gastric ulcers. Recently a surprisingly high prevalence of gastric ulcers was found within a broodmares population kept at pasture. These results suggest that multiple risk factors influence the occurrence and development of gastric ulceration in horses. Risk factors The ethiology of equine gastric syndrome is multifactorial and many risk factors have been studied including exercise, stress, stomach microbial infection, age, sex, breed, nonsteroidal drug administration, horse diet and feeding management. Various results were obtained. Intense exercise has been proven as a risk factor for EGUS. The mechanism is that compression of the stomach by the abdominal viscera and diaphragm leads to the release of acid contents into the proximal region of the stomach which is lined with squamous mucosa. This is thought to result in low ph secretion onto the nonglandular mucosa which could result in mucosal injury. The predisposition for ulceration of the nonglandular mucosa along the margo plicatus and on the lesser curvature in comparison with the saccus caecus, could be explained by this theory. It was proven that the prevalence and severity of gastric ulceration increases with the duration of race training, endurance training and simulated race training. According to the positive correlation between training or racing intensity and gastric ulcer occurrence, it is supposed that stress associated with these activities plays an important role in equine gastric ulcer pathogenesis. Severe stress may impair gastric mucosal flow leading to mucosal hypoxia, autodigestion and subsequent ulceration. It is considered a contributing factor for ulcers found in the glandular portion of the stomach. Stress accompanies exercise in horses as well as clinical disorders, environmental factors and other variables. In Australia, the horses trained in urban areas were 3,9 x more likely to have gastric ulcers in comparison with horses trained in non-urban areas. Time in work, crib-biting, difficulty maintaining bodyweight and playing a radio in the barn were all identifined as other risk factors.

Infection with Helicobacter pylori is of primary importance in the ethiology of gastric ulceration in man. The role of Helicobacter sp. in the horse is still unknown, but recently widely discussed. Helicobacter genus-specific (Helicobacter-like) DNA was found, but its relationship to mucosal lesion has not been proven. In addition a new Helicobacter species, Helicobacter equorum, was isolated from fecal samples of clinically healthy horses. These bacteria colonize the distal gastrointestinal tract and possibly do not play any role in EGUS. It has been confirmed that a diverse population of other bacteria live within the normal equine stomach. It was found that the diversity of bacteria adherent to the stomach lining decreases during ulceration, which implies the potential development of a dominant population of pathogenic organisms. Age and sex predisposition are frequently studied in connection with equine gastric ulceration, but a strong association is rarely found. Administration of nonsteroidal anti-inflammatory drugs (NSAIDs) was reported as a cause of gastric ulceration in many species. However the occurrence of ulcers is high even in horses with no history of drug use. Nonsteroidal anti-inflammatory drugs (phenylbutazone, flunixin meglumine), contrary to common belief, appear to have little impact on the development of gastric ulceration in horses. This is usually related to high dose and/or frequent administration of NSAIDs. Ketoprofen in comparison with phenylbutazon and flunixin meglumine has been found to have the less ulcerogenic effect to equine gastric mucosa. The less ulcerogenic effect of suxibuzone in comparison with phenylbutazone has recently been described. On the other hand, the more recent study did not show the difference between ulcerogenic effect of suxibuzone or phenylbutazone in horses given their therapeutic doses for two weeks. The NSAIDs combination therapy could result in a higher ulcerogenic risk to the horse than single treatment. A high grain low roughage diet has been proven to be a risk factor in gastric ulceration in the horses. High concentrate diets are high in digestible carbohydrates, which are fermented by bacteria, resulting in the production of VFAs. The role of VFAs in EGUS ethiopathogenesis is proven. Horses fed a concentrated diet (and low roughage) have higher prevalence and higher severity of EGUS in comparison with horses at pasture. Low roughage leads to decreased chewing and decreased saliva production. Salivary bicarbonate is a gastric buffer and protects the gastric mucosa against ulcer development. A high starch diet is fermented to VFAs and lactid acid. Therefore a high starch diet should be avoided in horses prone to gastric ulceration. Alfalfa hay was proven to protect equine gastric mucosa against ulceration by increasing stomach ph. Calcium and protein seem to be responsible for buffer effect of alfalfa hay. Gastric ph and ulcer score were lower in horses fed a diet including alfalfa hay in comparison with the same horses fed dietary brome or coastal Bermuda hay. Therefore, alfalfa hay may have a protective and antiulcer effect in horses. Grazing horses seem to have decreased EGUS prevalence because there is continuous saliva production which buffers the stomach environment. When feed is withheld from horses (before racing, in stabled horses during the night) gastric ph drops rapidly and the

nonglandular mucosa is exposed to an acid environment which predispose it to gastric ulceration. Intermittent and irregular feeding has been proven to cause and increase EGUS severity in the nonglandular stomach part. Clinical picture Clinical signs are non-specific in equine gastric ulceration. Acute and recurrent colic, diarrhoea (in foals), poor hair coat, poor appetite, weight loss, attitude changes, depression and poor performance are described in horses which suffered from gastric ulceration. Partial anorexia (poor general appetite) is one of the nonspecific clinical sign which accompany the syndrome of gastric ulceration in horses. Poor performance is frequently mentioned as a common sign of gastric ulceration, but only one study showed a direct association. Evaluation of a larger number of horses is needed to prove that poor performance is indeed a sign of equine gastric ulceration. Diagnosis Ante mortem diagnosis of equine gastric ulcer syndrome is based on history, clinical signs, gastroscopic examination and treatment response. Two point seventy-five meter to three point thirty meter gastroscopes are used to visualize the pyloric region and proximal duodenum. Many scoring systems have been developed for gastric ulcer classification in the horse. Biopsy samples are usually taken, but are not necessary for reliable diagnosis of EGUS. Other indirect diagnostic methods described include faecal occult blood testing (FOBT), sucrose permeability tests and serum alpha1-antitrypsin detection. There are no haematologic or biochemical markers which can be used to diagnose EGUS. If gastroscopy is not available it is recommend giving an antacid to which a local anesthetic (lidocain) is added through a nasogastric tube into the stomach of suspected horses. If gastric ulcers are the cause of abdominal pain, the pain should disappear within 15 minutes. If abdominal pain continues, then gastric ulcers are less likely and other possible causes should be considered. Complications Gastroduodenal ulceration can lead to pyloric or duodenal stenosis which is the most common cause of delayed gastric emptying syndrome (gastric outflow obstruction syndrome) in horses. Duodenal and gastric ulceration can be complicated by perforation leading to fatal septic peritonitis (especially in foals). The prevalence of duodenal perforation in adult horses is not well documented, but it appears to be low. Chronic cholangiohepatitis and pancreatitis following gastrodudenal ulceration and duodenal stenosis in foals was also described. Treatment and management

Current therapy for equine gastric ulcer syndrome tries to provide pain relief, ulcer healing and prevention of secondary complications. Medical treatment is based on blocking gastric acid secretion and encouraging the subsequent increase in gastric ph. This higher ph creates a suitable environment for ulcer healing. Surgical treatment is an option for delayed gastric empyting following EGUS. Prevention of recurrence is focused on dietary management. Treating pain originating from stomach ulceration in the horse is difficult. NSAIDs (especially repeated administration) should be avoided due to their role in EGUS pathogenesis. If necessary, ketoprofen or firocoxib may be used. The best choice seems to be use of alpha-2 adrenergic blocking agents (xylazine or detomidine, detomidine being longer acting) in combination with a syntetic opioid (butorphanol). CRI of lidocain is also recommended. Ulcer healing is promoted by antacid therapy. Proton pump inhibitors (omeprazole) offer a better option than H 2 antagonists (ranitidine, cimetidine) in stomach ulceration treatment. They can be used once daily and their antiulcer effectiveness is long acting. Omeprazole (4 mg/kg of body weight orally every 24 hours) inhibits gastric secretion in horses and it was proven to be effective in EGUS treatment and prevention. It is difficult to recommend the duration of pharmacologic treatment. Gastric ulcerations (similarly to skin wounds) in horses are individual. Endoscopic examination is recommended after two weeks of omeprazole treatment to evaluate ulcer healing. Medical treatment of horses with pyloric stenosis usually leads to a satisfactory clinical improvement. Permanent administration of omeprazole is recommended and these horses can survive for at least two years. Interruption of this therapy leads to a rapidly worsening status. Prokinetics can also form a part of the therapeutical regime for horses with gastric outflow obstruction (betanechol, cisaprid). Coating and binding agents such as sucralfate and bismuth subsalycylate can promote ulcer healing in the equine stomach. Sucralfate is the hydroxyl aluminium salt of sucrose octasulfate and in the stomach environment is converted to a sticky mass covering the mucosal lesions. Sucralfate is widely used in neonate foals where antacid therapy can lead to increased risk of nosocomial infections. The use of synthetic prostaglandin 1 (PGE 1) analog and somatostatin analog were studied in connection with EGUS. Prostaglandins would be most indicated in horses with NSAIDs administration or under stressful conditions. The cost limits their use in horses and it is contraindicated in pregnant and nursing mares because of its effect on the female reproductive tract. Even though the role of the recently found Helicobacter-like sp. in EGUS has not been confirmed yet there are some studies focusing on the influence of antibiotics and probiotic treatment on gastric ulcer healing in horses. Probiotic preparations containing

Lactobacillus sp. given to horses improved healing of spontaneously occurring nonglandular gastric ulceration. Moreover the severity of nonglandular ulceration decreased with antibiotic treatment (trimethoprim sulphadimidine administration). Surgical treatment (gastrojejunostomy, gastroduodenostomy) is an option for foals suffering from pyloric or duodenal ulceration or strictures accompanied by delayed gastric emptying syndrome. Prevention The reccurence of gastric ulceration in horses is common, therefore preventive strategies for environmental, nutritional and dietary management have been developed and their effect is discussed. As is mentioned above, exercise, dietary management, stall conditions and diet are all considered as risk factors for EGUS. The protective role of alfalfa hay and the risk from a high starch diet are discussed above within risk factors of EGUS section. The following section considers the role of dietary supplements in treatment and prevention of EGUS. Numerous dietary supplements have been developed for equine gastric ulcer supportive treatment but the majority of them lack scientific confirmation of their efficiency. For example, seabuckthorn berry extract does not have the effect of on equine gastric ulceration healing, but there is a possibility of a preventive use. Feeding dietary oils (corn oil) is a popular management practice for horses suffering from gastric ulceration. Some results confirmed their effect while the others did not. Dietary oils are at least the very good option for energy supplementation in horses instead of starch which is contraindicated in horses suffering from EGUS. Despite the widespread use of antiulcer treatment, the prevalence of EGUS remains high. This could be probably due to the cost of antiulcer medicaments which leads to shorter courses of treatment than is recommended, the administration of subtherapeutical doses or substitution of other ineffective medications or feed supplements. Further readings: Nadeau, J.A., Andrews, F.M. Equine gastric ulcer syndrome: The continuing conundrum. Equine Vet J, 2009, 41, 611-615. Videla, R., Andrews, F.M. New perspectives in equine gastric ulcer syndrome. Vet Clin North Am Equine Pract, 2009, 25, 2, 283-301.